【1 月 3 日|和黄医药新药上市申请获受理并优先审评】和黄医药昨日公布沃瑞沙和泰瑞沙的联合疗法的新药上市申请已获国家药监局受理并予以优先审评。花旗称,联合疗法相较于同行具优势,因特定生物标志物 MET 高,口服且无化疗疗程。公司以 6.08 亿美元出售上海和记医药 45%股权,相当于 14 至 15 倍市盈率,将强化资本和债务结构,集中资源于核心业务。花旗指出,该股近三月表现疲弱,因沃瑞沙在美国...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.